CRC
Oncology · 2005–2024
22decisions
8medicines
6carried consumer input
13individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bevacizumab Metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small cell lung cancer, advanced… | Mar 2024 | Recommended with restriction | 1 individuals |
| encorafenib Treatment of patients with BRAF V600E variant metastatic colorectal cancer (mCRC) who have received prior systemic therapy, in combination with cetuximab (an… | May 2021 | Deferred | 1 individuals Bowel Cancer Australia · Rare Cancers Australia |
| encorafenib Treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation who have received prior systemic therapy, in combination with… | Mar 2021 | Deferred | 1 individuals Bowel Cancer Australia · Rare Cancers Australia |
| pembrolizumab First-line treatment of patients with Stage IV (metastatic) colorectal cancer with deficient mismatch repair (dMMR) who have not previously received systemic… | Mar 2021 | Recommended with restriction | 9 individuals Medical Oncology Group |
| bevacizumab Biosimilar bevacizumab indicated for the same indications as the reference product Avastin, including first-line treatment of patients with Stage IV… | Nov 2021 | Recommended with restriction | unclear |
| trifluridine with tipiracil Treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies… | Mar 2018 | Not recommended | input received |
| panitumumab First-line treatment of RAS wild-type metastatic colorectal cancer in combination with oxaliplatin-based chemotherapy. | Mar 2015 | Recommended | no section in document |
| regorafenib Initial or continuing treatment of metastatic colorectal cancer following failure of, or intolerance to, other treatment options (fluoropyrimidine,… | Jul 2014 | Not recommended | 1 individuals |
| panitumumab Treatment of K-RAS wild-type metastatic colorectal cancer as monotherapy or in combination with FOLFIRI after failure of first-line chemotherapy, and in… | Mar 2013 | Recommended | no section in document |
| panitumumab Treatment of K-RAS wild-type metastatic colorectal cancer in patients who have failed first-line chemotherapy, as monotherapy or in combination with… | Nov 2013 | Recommended with restriction | no section in document |
| capecitabine adjuvant treatment of stage III (Dukes C) colon cancer, following complete resection of the primary tumour; either as monotherapy or in combination with… | Mar 2011 | Recommended | no section in document |
| capecitabine adjuvant treatment of stage III (Dukes C) colon cancer, following complete resection of the primary tumour; either as monotherapy or in combination with… | Mar 2011 | Recommended | no section in document |
| cetuximab treatment of K-RAS wild type metastatic colorectal cancer as monotherapy or in combination with chemotherapy following failure of chemotherapy | Jul 2010 | Recommended with restriction | no section in document |
| cetuximab Treatment of patients with K-RAS wild-type metastatic colorectal cancer as monotherapy or in combination with irinotecan-based chemotherapy following failure… | Jul 2010 | Recommended with restriction | no section in document |
| cetuximab treatment of patients with metastatic colorectal cancer following failure of irinotecan and failure of or intolerance to oxaliplatin. | Mar 2009 | Not recommended | no section in document |
| Bevacizumab Initial treatment of metastatic colorectal cancer in previously untreated patients with a WHO performance status of 0 or 1 in combination with chemotherapy. | Jul 2008 | Recommended with restriction | no section in document |
| bevacizumab Treatment of metastatic colorectal cancer in previously untreated patients (first-line) and in patients with disease progression following first-line… | Mar 2008 | Not recommended | no section in document |
| cetuximab Treatment of patients with metastatic colorectal cancer following failure of irinotecan and failure of or intolerance to oxaliplatin, with wild-type KRAS… | Nov 2008 | Recommended | no section in document |
| panitumumab Treatment of K-RAS wild-type metastatic colorectal cancer after failure of treatment with fluoropyrimidine, irinotecan, and oxaliplatin. | Nov 2008 | Recommended | no section in document |
| capecitabine adjuvant treatment of Dukes’ C colon cancer following complete resection of the primary tumour | Nov 2005 | Recommended with restriction | no section in document |
| cetuximab treatment for metastatic colorectal cancer (MCRC) where the current standard chemotherapeutic options have failed | Nov 2005 | Not recommended | no section in document |
| capecitabine Adjuvant treatment of patients with Dukes' C colon cancer following complete resection of the primary tumour. | Nov 2005 | Recommended with restriction | no section in document |
Who spoke
Bowel Cancer Australia · Rare Cancers Australia · Medical Oncology Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 6 of 8 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.